These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 9893764)

  • 1. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD.
    Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H
    Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
    Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
    J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels of soluble Fas ligand and soluble Fas in patients with chronic obstructive pulmonary disease.
    Takabatake N; Nakamura H; Inoue S; Terashita K; Yuki H; Kato S; Yasumura S; Tomoike H
    Respir Med; 2000 Dec; 94(12):1215-20. PubMed ID: 11192958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis.
    Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H
    Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure.
    Kinugawa T; Kato M; Yamamoto K; Hisatome I; Nohara R
    Int Heart J; 2012; 53(3):182-6. PubMed ID: 22790687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
    Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
    Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
    Mouawad R; Khayat D; Soubrane C
    Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of circulating apoptosis mediators and proinflammatory cytokines in patients with idiopathic hypertrophic cardiomyopathy: comparison between nonobstructive and dilated-phase hypertrophic cardiomyopathy.
    Zen K; Irie H; Doue T; Takamiya M; Yamano T; Sawada T; Azuma A; Matsubara H
    Int Heart J; 2005 Mar; 46(2):231-44. PubMed ID: 15876807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C.
    Toyoda M; Kakizaki S; Horiguchi N; Sato K; Takayama H; Takagi H; Nagamine T; Mori M
    Liver; 2000 Jul; 20(4):305-11. PubMed ID: 10959809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
    Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
    Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure.
    Adamopoulos S; Parissis J; Karatzas D; Kroupis C; Georgiadis M; Karavolias G; Paraskevaidis J; Koniavitou K; Coats AJ; Kremastinos DT
    J Am Coll Cardiol; 2002 Feb; 39(4):653-63. PubMed ID: 11849865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysregulation of apoptosis in scorpion envenomed children: its reflection on their outcome.
    Meki AR; Hasan HA; El-Deen ZM; Bakkar S
    Toxicon; 2003 Sep; 42(3):229-37. PubMed ID: 14559073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating levels of soluble Fas ligand in cachexic patients with COPD are higher than those in non-cachexic patients with COPD.
    Takabatake N; Arao T; Sata M; Inoue S; Abe S; Shibata Y; Kubota I
    Intern Med; 2005 Nov; 44(11):1137-43. PubMed ID: 16357450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of soluble Fas/APO-1 receptor in human retroviral infection and associated diseases.
    Kamihira S; Yamada Y; Hiragata Y; Yamaguchi T; Izumikawa K; Matsuo Y; Sugahara K; Tsuruta K; Atogami S; Tsukasaki K; Maeda T; Tomonaga M
    Intern Med; 1997 Mar; 36(3):166-70. PubMed ID: 9144006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged intrathecal release of soluble Fas following severe traumatic brain injury in humans.
    Lenzlinger PM; Marx A; Trentz O; Kossmann T; Morganti-Kossmann MC
    J Neuroimmunol; 2002 Jan; 122(1-2):167-74. PubMed ID: 11777556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction.
    Ohtsuka T; Hamada M; Sasaki O; Suzuki M; Hara Y; Shigematsu Y; Ohtani T; Honda T; Hiwada K
    Coron Artery Dis; 1999 Jun; 10(4):221-5. PubMed ID: 10376200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases.
    Nozawa K; Kayagaki N; Tokano Y; Yagita H; Okumura K; Hasimoto H
    Arthritis Rheum; 1997 Jun; 40(6):1126-9. PubMed ID: 9182923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.
    Kawahito K; Misawa Y; Fuse K
    Artif Organs; 2000 Aug; 24(8):628-31. PubMed ID: 10971250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma sFas and sFas ligand levels in patients with thrombotic thrombocytopenic purpura and in those with disseminated intravascular coagulation.
    Hori Y; Wada H; Mori Y; Shimura M; Hiyoyama K; Nakasaki T; Nishii K; Tamaki S; Nishikawa M; Deguchi K; Minami N; Shiku H
    Am J Hematol; 1999 May; 61(1):21-5. PubMed ID: 10331507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.